{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:05Z","timestamp":1792612265142,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bulcan.2020.12.001","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T15:29:14Z","timestamp":1610119754000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cancer \u00e9pidermo\u00efde du canal anal m\u00e9tastatique en 2020"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-7119","authenticated-orcid":false,"given":"Stefano","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4126-5553","authenticated-orcid":false,"given":"Laurie","family":"Spehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.12.001_bib0300","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0305","article-title":"International trends in anal cancer incidence rates","volume":"39","author":"Islami","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0310","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36\u00a0Gy elective node irradiation dose in anal cancer","volume":"116","author":"L\u00e9pinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0315","unstructured":"Cancer Stat Facts: Anal Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html [Acc\u00e9d\u00e9 le 25 d\u00e9cembre 2020]."},{"key":"10.1016\/j.bulcan.2020.12.001_bib0320","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0325","unstructured":"Stouvenot M, Vuitton L, Meurisse A, Spehner L, Jacquin M, Fein F, et al. Prise en charge du carcinome \u00e9pidermo\u00efde du canal anal avanc\u00e9 n.d."},{"key":"10.1016\/j.bulcan.2020.12.001_bib0330","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0335","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3\u00a0trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0340","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-Term Update of US GI Intergroup RTOG 98-11\u00a0Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil\/Mitomycin Versus Fluorouracil\/Cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0345","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72\u00a0factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0355","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.25188","article-title":"Prognostic factors derived from a prospective database dictate clinical biology of anal cancer","volume":"116","author":"Ajani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0360","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03\u00a0Trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0365","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3566-0","article-title":"Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02\u00a0study)","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0375","unstructured":"Le Th\u00e9saurus National de Canc\u00e9rologie Digestive (TNCD)\u00a0: cancer du canal anal. https:\/\/www.snfge.org\/content\/6-cancer-du-canal-anal."},{"key":"10.1016\/j.bulcan.2020.12.001_bib0380","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0385","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2\u00a0study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0390","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115\u00a0patients from updated data of Epitopes-HPV01\u00a0and Epitopes-HPV02\u00a0studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0395","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0400","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0405","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-18-3982","article-title":"Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral","volume":"7","author":"Morris","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.02137","article-title":"How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0415","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a Role of the PD-1:PD-L1\u00a0Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0420","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0425","doi-asserted-by":"crossref","first-page":"20902","DOI":"10.18632\/oncotarget.3939","article-title":"Gene expression patterns through oral squamous cell carcinoma development: PD-L1\u00a0expression in primary tumor and circulating tumor cells","volume":"6","author":"Oliveira-Costa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0430","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2\u00a0study","volume":"18","author":"Van Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0435","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1\u00a0antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0440","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158\u00a0study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0445","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028\u00a0and KEYNOTE-158\u00a0studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0450","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"LBA42\u00a0POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0455","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.513","article-title":"402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment","volume":"31","author":"Lonardi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0460","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"403MO Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0465","first-page":"3783","article-title":"Restoration of wild-type p16\u00a0down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas","volume":"59","author":"Harada","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0470","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0475","first-page":"1","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer","volume":"5","author":"Massarelli","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0480","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.virol.2008.02.025","article-title":"HPV E7\u00a0contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function","volume":"375","author":"Liu","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0485","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/cgt.2009.24","article-title":"Paclitaxel combined with siRNA targeting HPV16\u00a0oncogenes improves cytotoxicity for cervical carcinoma","volume":"16","author":"Liu","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0490","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.3390\/ijms21186838","volume":"21","author":"Spehner","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0495","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-12-0896","article-title":"Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor","volume":"18","author":"Dosset","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0500","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","article-title":"Analysis of Spontaneous Tumor-Specific CD4\u00a0T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response","volume":"18","author":"Godet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0505","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-015-1782-5","article-title":"Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study","volume":"65","author":"Mandruzzato","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0510","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","article-title":"Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy","volume":"15","author":"Cabel","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0515","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","article-title":"Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance","volume":"37","author":"Kilgour","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0520","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.humpath.2012.08.019","article-title":"Signature patterns of human papillomavirus type 16\u00a0in invasive anal carcinoma","volume":"44","author":"Valmary-Degano","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0525","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/ijc.30863","article-title":"HPV circulating tumor DNA to monitor the efficacy of anti-PD-1\u00a0therapy in metastatic squamous cell carcinoma of the anal canal: a case report","volume":"141","author":"Cabel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cjp2.47","article-title":"Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma","volume":"2","author":"Jeannot","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0535","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/bjc.2017.258","article-title":"Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma","volume":"117","author":"Lee","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0540","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0545","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0550","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-020-06841-1","article-title":"Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0555","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/2326-6066.CIR-19-0326","article-title":"Immunoregulation and Clinical Implications of ANGPT2\/TIE2(+) M-MDSC Signature in Non-Small Cell Lung Cancer","volume":"8","author":"Lauret Marie Joseph","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0565","first-page":"1","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0570","first-page":"1","article-title":"Nintedanib and a bi-specific anti-VEGF\/Ang2\u00a0nanobody selectively prevent brain metastases of lung adenocarcinoma cells","volume":"14","author":"Kovalchuk","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0575","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.12.001_bib0580","doi-asserted-by":"crossref","first-page":"S1193","DOI":"10.1016\/j.annonc.2020.08.2299","article-title":"LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577\u00a0study","volume":"31","author":"Kelly","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2020.12.001_bib0585","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ijc.32804","article-title":"HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers","volume":"147","author":"Veyer","year":"2020","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2020.12.001_bib0590","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02\u00a0Trial","volume":"25","author":"Bernard-Tessier","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120305051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120305051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:34Z","timestamp":1757792014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120305051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0007455120305051"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.12.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer \u00e9pidermo\u00efde du canal anal m\u00e9tastatique en 2020","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}